ASS1 and neoplasm: To date, a number of mechanisms have been described for ADI-PEG20 resistance including ASS1 re-expression, antigenicity of the drug itself, and increased autophagy, and tumor-associated stromal cells may also provide arginine to ASS1-deficient tumor cells to counter the effect of ADI-PEG20.9